LUPIN2,074.00

Lupin Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMACIPLADRREDDYALKEMFORTISAUROPHARMALAURUSLABSMANKINDMcap ₹94,823 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)436.53448.44480.41480.41
Receivable Days (DSO)85.5888.3686.2286.22
Payable Days (DPO)260.66242.23329.56316.87
Cash Conversion Cycle (days)261.45294.57237.07249.76
Working Capital Turnover4.052.902.462.63
Asset Turnover0.830.780.730.73
Cash Conversion (CFO/Net Income)1.800.131.411.41
CFO/EBITDA0.920.080.860.86
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.